|
MarketWatch
Spending On Postapproval Drug Safety
David B. Ridley,
Judith M. Kramer,
Hugh H. Tilson,
Henry G. Grabowski and
Kevin A. Schulman
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on postapproval safety per company in 2003 was $56 million (0.3 percent of sales). Assuming a constant safety-to-sales ratio, we estimated that total spending on postapproval safety by the top twenty drug manufacturers was $800 million in 2003. We also examined, using regression analysis, the relationship between the number of safety personnel and the number of initial adverse-event reports. This study offers information for the debate on proposed changes to safety surveillance.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. D. Reed, R. M. Califf, and K. A. Schulman
How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation
Health Aff.,
September 1, 2006;
25(5):
1309 - 1317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Ridley, H. G. Grabowski, and J. L. Moe
Developing drugs for developing countries.
Health Aff.,
March 1, 2006;
25(2):
313 - 324.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Comments:
Read all Comments
- Of One $56M Apple and Many Uncounted Oranges: Spending on Postapproval Drug Safety
- Ivo L. Abraham, et al.
- Health Affairs, 28 Mar 2006
[Full text]
- Reply From The Authors
- David B. Ridley, et al.
- Health Affairs, 6 Apr 2006
[Full text]
|